Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Public ClinicalTrials.gov record NCT03172624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
Study identification
- NCT ID
- NCT03172624
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2017
- Primary completion
- Dec 17, 2024
- Completion
- Dec 17, 2024
- Last update posted
- Dec 17, 2025
2017 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 2
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York | 11570 | — |
| Memorial Sloan Kettering Nassau | Uniondale | New York | 11553 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Salivary Gland Cancer trials
Other public records listing Salivary Gland Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07667400: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer Not yet recruiting
- NCT02012699: Integrated Cancer Repository for Cancer Research Recruiting
- NCT05074940: Amivantamab in Adenoid Cystic Carcinoma Active, not recruiting
- NCT07124000: DESTINY-PANTUMOUR04 Recruiting
- NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Recruiting
- NCT06695845: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03172624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03172624 live on ClinicalTrials.gov.